Mary Guckian

1000 citations
13 papers · 465 indexed · h-index 10
Topics
Immune Cell Function and Interaction (3 papers)SARS-CoV-2 and COVID-19 Research (2 papers)HIV Research and Treatment (2 papers)

In The Last Decade

Mary Guckian

13 papers receiving 454 citations

Peers

Mary Guckian
Comparison fields: 5 of 70
  • Immunology 209
  • Molecular Biology 111
  • Epidemiology 79
  • Hematology 78
  • Oncology 77
Replace F. Touraine with:
F. Touraine France
Michał Abel France
Florence Capilla France
Mark Jacobs United States
Tomoteru Kamimura Japan
Ren Zhu France
Sun-Young Han South Korea
Roger H. Halterman United States
Hai-Chon Lee United States
S Okamura Japan
Mary Guckian relative to F. Touraine France F. Touraine's profile →
Citations per field
00.5×10×20×29×
F. Touraine · 1×
Citations per year

Countries citing papers authored by Mary Guckian

Since Specialization
Citations

This map shows the geographic impact of Mary Guckian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Guckian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Guckian more than expected).

Fields of papers citing papers by Mary Guckian

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Guckian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Guckian. The network helps show where Mary Guckian may publish in the future.

Co-authorship network of co-authors of Mary Guckian

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Guckian. A scholar is included among the top collaborators of Mary Guckian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Guckian. Mary Guckian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
#WorkIndexed citations
1 3
2 25
3 55
4 4
5 56
6 10
7 72
8 50
9
CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production.
86
10 39
11 33
12 7
13 25

About Mary Guckian

Mary Guckian is a scholar working on Virology, Immunology and Dermatology, having authored 13 papers that have together received 465 indexed citations. Recurring topics across this work include Immune Cell Function and Interaction (3 papers), SARS-CoV-2 and COVID-19 Research (2 papers) and HIV Research and Treatment (2 papers). The work is most often cited by research in Immunology (209 citations), Virology (34 citations) and Hematology (78 citations). Mary Guckian has collaborated with scholars based in United Kingdom, Ireland and Switzerland. Frequent co-authors include Angus Dalgleish, J B Marriott, Sharon Cookson, David Stirling, Michael Westby, Stephen Goodbourn, George W. Muller, Mary Norval, Neil K. Gibbs and Steve Nicholson. Their work appears in journals such as Journal of Clinical Investigation, The Journal of Immunology and Journal of the American Society of Nephrology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026